Amarin Corp Plc (AMRN)

[relocatedmetsfan]

Rafun - “argue the exact same points”


Any other generics that were not included in this case at one point in time will argue the same exact points in any subsequent trial.

They will also have to argue how they will not infringe on REDUCE-IT patents, which are now in the OB. That, I believe, will be a much harder bar to clear, especially given the expert witness testimony provided in this case.